Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2018 | Inflammatory Disorders

Checkpoint inhibitor-induced uveitis: a case series

Authors: Christopher D. Conrady, Marissa Larochelle, Paula Pecen, Alan Palestine, Akbar Shakoor, Ajay Singh

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2018

Abstract

Purpose

Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs.

Methods

Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers.

Results

All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease.

Conclusions

Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist.

Available only for authorised users

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988CrossRefPubMed

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322. https://doi.org/10.1126/science.291.5502.319 CrossRefPubMed

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727. https://doi.org/10.1038/nri1936 CrossRefPubMed

Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265–276. https://doi.org/10.1016/j.it.2015.02.008 CrossRefPubMedPubMedCentral

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800. https://doi.org/10.1038/nm730 CrossRefPubMed

Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84–88. https://doi.org/10.1038/nm1517 CrossRefPubMed

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

Mandala M, De Logu F, Merelli B, Nassini R, Massi D (2017) Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab Investig 97:166–175. https://doi.org/10.1038/labinvest.2016.132 CrossRefPubMed

Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7:122–136. https://doi.org/10.1177/1758834014566428 CrossRefPubMedPubMedCentral

10.

Draganova D, Kerger J, Caspers L, Willermain F (2015) Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthal Inflamm Infect 5:17. https://doi.org/10.1186/s12348-015-0049-9 CrossRef

11.

Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282:2263–2266CrossRefPubMed

12.

Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550. https://doi.org/10.1002/ijc.21155 CrossRefPubMed

13.

Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 Suppl 4:2–9. https://doi.org/10.1634/theoncologist.13-S4-2 CrossRefPubMed

14.

Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372–8377. https://doi.org/10.1073/pnas.1533209100 CrossRefPubMedPubMedCentral

15.

Karlin J, Gentzler R, Golen J (2016) Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 1–3. https://doi.org/10.1080/09273948.2016.1215473

16.

Aaberg MT, Aaberg TM Jr (2016) Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. https://doi.org/10.1097/ICB.0000000000000368

17.

Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50:e2–e4. https://doi.org/10.1016/j.jcjo.2014.10.010 CrossRefPubMed

18.

Kahloun R, Mbarek S, Khairallah-Ksiaa I, Jelliti B, Yahia SB, Khairallah M (2013) Branch retinal artery occlusion associated with posterior uveitis. J Ophthal Inflamm Infect 3:16. https://doi.org/10.1186/1869-5760-3-16 CrossRef

19.

Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4:272. 10.21037/atm.2016.07.10 CrossRefPubMedPubMedCentral

20.

Maezawa N, Yano A (1984) Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol Immunol 28:219–231CrossRefPubMed

21.

Caspi RR (2010) A look at autoimmunity and inflammation in the eye. J Clin Invest 120:3073–3083. https://doi.org/10.1172/JCI42440 CrossRefPubMedPubMedCentral

22.

Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 158:831–837.e832. https://doi.org/10.1016/j.ajo.2014.07.003 CrossRefPubMed

Title: Checkpoint inhibitor-induced uveitis: a case series
Authors: Christopher D. Conrady
Marissa Larochelle
Paula Pecen
Alan Palestine
Akbar Shakoor
Ajay Singh
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3835-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Checkpoint inhibitor-induced uveitis: a case series

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Influence of LASEK on Schiøtz, Goldmann and dynamic contour Tonometry

AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration

Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial

Repeatability assessment of anterior segment biometric measurements under accommodative and nonaccommodative conditions using an anterior segment OCT

Multimodal imaging of linear lesions in the fundus of pathologic myopic eyes with macular lesions

Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits